Biocon’s $3.3bn Biosimilars Big Leap Also Marks Viatris’ 'Smart' Exit, Albeit Toehold
Executive Summary
Biocon seals milestone deal to acquire Viatris’s biosimilars assets for up to $3.3bn, accelerating its direct commercialization push across key markets and also bringing with it rights to key in-licensed therapies, including biosimilar adalimumab, and an option to acquire the US firm’s rights for biosimilar aflibercept.
You may also be interested in...
Biocon: Slow Humira Biosimilar Uptake But Payer Landscape Evolving
Biocon bets on dual pricing strategy in the US amid a “more gradual” than expected uptake of biosimilar adalimumab but emphasizes that payer positions aren’t “definitive” yet.
Biocon: Slow Humira Biosimilar Uptake But Payer Landscape Evolving
Biocon bets on dual pricing strategy in the US amid a “more gradual” than expected uptake of biosimilar adalimumab but emphasizes that payer positions aren’t “definitive” yet.
Biocon Pumps Up For Adalimumab US Debut Amid Payer ‘Steady State’
Biocon is confident of its “four channel strategy” for the upcoming debut of biosimilar Humira in the US and also asserts it’s well positioned to compete when price cuts come into play for Sanofi’s Lantus next year.